文献速递肿瘤 PET/CT放射性药物与辐射防护

[99mTc]Tc标记抗EpCAM纳米抗体的临床前评估:用于免疫SPECT/CT成像EpCAM受体表达

Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-01-11

本研究制备了位点特异性[99mTc]Tc标记的EpCAM靶向纳米抗体[99mTc]Tc-NB4,在HT-29(EpCAM阳性)和HL-60(EpCAM阴性)细胞及皮下肿瘤模型和淋巴结转移模型中评估其体外特性和体内SPECT/CT成像能力。结果显示[99mTc]Tc-NB4具有高EpCAM特异性,血液和正常器官清除快(肾脏除外),HT-29肿瘤清晰显像,且可清晰成像肿瘤引流淋巴结。

要点

  • [99mTc]Tc-NB4在体外和体内均显示高EpCAM特异性。
  • HT-29肿瘤摄取从注射后0.5小时的3.77±0.39%ID/g持续增至12小时的5.53±0.82%ID/g。
  • [99mTc]Tc-NB4 SPECT/CT可清晰成像肿瘤引流淋巴结。

核心结论

  • [99mTc]Tc-NB4是一种广谱、特异、灵敏的SPECT放射性示踪剂,可用于上皮来源癌症EpCAM表达的无创成像,并显示出良好的临床转化潜力。

研究设计与样本

  • 本研究为临床前研究,制备了位点特异性[99mTc]Tc标记的EpCAM靶向纳米抗体[99mTc]Tc-NB4。
  • 体外特性在HT-29(EpCAM阳性)和HL-60(EpCAM阴性)细胞中研究。
  • 体内研究采用小动物SPECT/CT在皮下肿瘤模型和淋巴结转移模型中进行。

主要发现

  • [99mTc]Tc-NB4在体外和体内均显示高EpCAM特异性。
  • SPECT/CT显示[99mTc]Tc-NB4从血液和正常器官快速清除(肾脏除外),HT-29肿瘤清晰显像,与HL-60肿瘤形成对比。
  • [99mTc]Tc-NB4在HT-29肿瘤中的摄取从注射后0.5小时的3.77±0.39%ID/g持续增至12小时的5.53±0.82%ID/g。
  • [99mTc]Tc-NB4 SPECT/CT可清晰成像肿瘤引流淋巴结。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Overexpression of epithelial cell adhesion molecule (EpCAM) plays essential roles in tumorigenesis and tumor progression in almost all epithelium-derived cancer. Monitoring EpCAM expression in tumors can be used for the diagnosis, staging, and prognosis of cancer patients, as well as guiding the individualized treatment of EpCAM-targeted drugs. In this study, we described the synthesis and evaluation of a site-specifically [99mTc]Tc-labeled EpCAM-targeted nanobody for the SPECT/CT imaging of EpCAM expression. METHODS: We first prepared the [99mTc]Tc-HYNIC-G4K; then, it was site-specifically connected to EpCAM-targeted nanobody NB4. The in vitro characteristics of [99mTc]Tc-NB4 were investigated in HT-29 (EpCAM positive) and HL-60 (EpCAM negative) cells, while the in vivo studies were performed using small-animal SPECT/CT in the subcutaneous tumor models and the lymph node metastasis model to verify the specific targeting capacity as well as the potential applications of [99mTc]Tc-NB4. RESULTS: [99mTc]Tc-NB4 displayed a high EpCAM specificity both in vitro and in vivo. SPECT/CT imaging revealed that [99mTc]Tc-NB4 was cleared rapidly from the blood and normal organs except for the kidneys, and HT-29 tumors were clearly visualized in contrast with HL-60 tumors. The uptake value of [99mTc]Tc-NB4 in HT-29 tumors was increased continuously from 3.77 ± 0.39%ID/g at 0.5 h to 5.53 ± 0.82%ID/g at 12 h after injection. Moreover, the [99mTc]Tc-NB4 SPECT/CT could clearly image tumor-draining lymph nodes. CONCLUSION: [99mTc]Tc-NB4 is a broad-spectrum, specific, and sensitive SPECT radiotracer for the noninvasive imaging of EpCAM expression in the epithelium-derived cancer and revealed a great potential for the clinical translation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu T, Wu Y, Shi L, et al. Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECT/CT. Eur J Nucl Med Mol Imaging. 2022. PMID: 35013776. doi:10.1007/s00259-021-05670-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。